免疫分析
医学
肿瘤标志物
癌
肺癌
重组DNA
肺
内科学
胃肠病学
癌症
化学
免疫学
抗体
生物化学
基因
作者
Katsumi Aoyagi,Yuichiro Miyake,Kenichi Urakami,T Kashiwakuma,Akira Hasegawa,Tetsuro Kodama,Ken Yamaguchi
出处
期刊:Clinical Chemistry
[Oxford University Press]
日期:1995-04-01
卷期号:41 (4): 537-543
被引量:68
标识
DOI:10.1093/clinchem/41.4.537
摘要
Previously, using recombinant human progastrin-releasing peptide (ProGRP)(31-98), we developed a RIA for ProGRP(31-98) and demonstrated that the determination of serum ProGRP(31-98) was a reliable marker for small-cell lung carcinoma (SCLC) (Miyake et al., Cancer Res 1994;54:2136-40). Aiming for a more convenient assay system, we have now developed and evaluated a highly sensitive and specific ELISA for ProGRP(31-98). Only 50 microL of nonextracted serum is needed, and results are obtained in only 2 h. Intraassay and between-day CVs were 1.7-4.6% and 4.2-6.8%, respectively. The log-log calibration curve was linear to 1000 ng/L, and analytical recovery was 91.5-108.7%. The detection limit of this assay, 1.9 ng/L, means that basal concentrations of ProGRP(31-98) were detectable in all healthy subjects. The cutoff value, based on the mean + 3 SD of concentrations in 247 healthy subjects, was set to 45.1 ng/L. Serum concentrations exceeded this value in 18 of 25 SCLC patients, similar to the frequency of increased values found by RIA previously. In contrast, the frequency of increased serum ProGRP(31-98) in patients with nonmalignant pulmonary diseases or non-SCLC was quite low: 0% and 5.0%, respectively. Such results may justify a clinical trial for evaluating this ELISA for the diagnosis and monitoring of SCLC patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI